홈 > 시장보고서 > 의약품 > 암

시장보고서

상품코드

1522085

세계의 피부암 진단 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 검사 유형별, 최종 용도별, 지역별, 전망과 예측(2024-2031년)

Global Skin Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type, By Test Type, By End-use, By Regional Outlook and Forecast, 2024 - 2031

발행일: 2024년 07월 | 리서치사:

KBV Research | 페이지 정보: 영문 219 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

피부암 진단 시장 규모는 예측 기간 중 5.3%의 CAGR로 시장 성장하며, 2031년까지 128억 달러에 달할 것으로 예상되고 있습니다.

또한 세계 인구의 고령화에 따라 피부암 발병률은 특히 50세 이상에서 증가할 것으로 예상되며, 보다 종합적인 진단 방법 및 의료 서비스에 대한 수요가 증가할 것으로 예상됩니다.

그러나 피부경, 공초점 현미경, 첨단 영상 시스템과 같은 첨단 장비는 피부암을 정확하고 조기에 발견할 수 있는 최첨단 기술입니다. 그러나 이러한 툴의 개발 및 제조에는 많은 투자가 필요하며, 이는 시장 가격에 반영되어 있습니다.

유형별 전망

암 유형에 따라 시장은 흑색종과 비흑색종으로 분류됩니다. 비흑색종 부문은 2023년 시장에서 72%의 매출 점유율을 차지했습니다. 가장 흔한 두 가지 형태의 피부암인 기저세포암(BCC)과 편평상피암(SCC)이 이 부문을 이끄는 주요 요인입니다.

검사 유형 전망

검사 유형에 따라 시장은 피부경 검사, 피부 생검, 림프절 생검, 영상 검사 등으로 분류됩니다. 영상 검사 부문은 2023년 시장에서 27%의 매출 점유율을 기록했습니다.

최종 용도 전망

최종 용도별로 시장은 병원 및 클리닉, 연구소, 기타로 나뉩니다. 병원 및 클리닉 부문은 2023년 시장에서 51%의 매출 점유율을 차지했습니다. 잠재적인 피부암을 포함한 피부 질환으로 인해 치료가 필요한 환자들은 병원 및 클리닉을 주요 치료 장소로 이용하고 있습니다.

지역 전망

지역별로 시장은 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 나뉘어 분석되었습니다. 아시아태평양은 2023년 피부암 진단 시장에서 23%의 매출 점유율을 차지할 것으로 예상됩니다. 호주와 같은 국가에서는 자외선 노출이 많기 때문에 피부암 발생률이 높지만 중국, 인도, 일본과 같은 신흥 시장에서는 피부암 사례가 증가하고 있습니다.

북미
- 북미의 시장 : 국가별
  - 미국
  - 캐나다
  - 멕시코
  - 기타 북미 지역
유럽
- 유럽의 시장 : 국가별
  - 독일
  - 영국
  - 프랑스
  - 러시아
  - 스페인
  - 이탈리아
  - 기타 유럽 지역
아시아태평양
- 아시아태평양 시장 : 국가별
  - 중국
  - 일본
  - 인도
  - 한국
  - 싱가포르
  - 말레이시아
  - 기타 아시아태평양
라틴아메리카·중동 및 아프리카
- 라틴아메리카·중동 및 아프리카의 시장 : 국가별
  - 브라질
  - 아르헨티나
  - 아랍에미리트
  - 사우디아라비아
  - 남아프리카공화국
  - 나이지리아
  - 기타 라틴아메리카·중동 및 아프리카 지역

제8장 기업 개요

Castle Biosciences, Inc
Bausch Health Companies, Inc(DermTech, Inc.)
Canfield Scientific, Inc
DermaSensor, Inc
F Hoffmann-La Roche Ltd.
Neogenomics, Inc
Quest Diagnostics Incorporated
Digital Diagnostics, Inc(3Derm Systems, Inc.)
FotoFinder Systems GmbH
VERISKIN INC

제9장 피부암 진단 시장의 성공 필수 조건

KSA 24.08.02

The Global Skin Cancer Diagnostics Market size is expected to reach $12.8 billion by 2031, rising at a market growth of 5.3% CAGR during the forecast period.

A combination of high skin cancer prevalence, advanced healthcare infrastructure, and strong government support drives the market in this region. Skin cancer, particularly non-melanoma and melanoma is highly prevalent in the United States, with millions of cases diagnosed annually. This widespread incidence necessitates extensive diagnostic services. Advanced healthcare systems in North America, particularly in the United States and Canada, are equipped with state-of-the-art diagnostic tools such as dermatoscopes, confocal microscopes, and AI-enhanced imaging systems, which enhance diagnostic accuracy and efficiency. Thus, the North America region acquired 37% revenue share in the market 2023.

The proportion of people diagnosed with melanoma around the world has been gradually climbing, which has led to a rise in the demand for cutting-edge diagnostic tools and technology. Globally, 132,000 melanoma skin cancers and 2 to 3 million non-melanoma skin cancers are diagnosed annually, according to the World Health Organization (WHO).

Additionally, it is projected that the incidence of skin cancer will increase, particularly among those who are 50 years of age or older, as the global population advances in age. Consequently, the demand for more comprehensive diagnostic methods and healthcare services will increase.

However, advanced equipment such as dermatoscopes, confocal microscopes, and sophisticated imaging systems represent cutting-edge technology for accurate and early skin cancer detection. However, the development and manufacturing of these tools involve substantial investment, which is reflected in their market prices.

Type Outlook

Based on cancer type, the market is characterized into melanoma and non-melanoma. The non-melanoma segment garnered 72% revenue share in the market in 2023. Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), the two most prevalent forms of skin cancer, are the primary factors driving the segment.

Test Type Outlook

On the basis of test type, the market is classified into dermatoscopy, skin biopsy, lymph node biopsy, imaging tests, and others. The imaging tests segment recorded 27% revenue share in the market in 2023.

End-use Outlook

By end-use, the market is divided into hospital & clinics, laboratories, and others. The hospital & clinics segment witnessed 51% revenue share in the market in 2023. Patients who require medical attention for skin issues, including potential skin cancer, are served by hospitals and clinics as their primary sites of care.

Reginal Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific segment acquired 23% revenue share in the skin cancer diagnostics market in 2023. Countries like Australia face high skin cancer rates due to significant UV exposure while emerging markets such as China, India, and Japan are witnessing increasing skin cancer cases.

List of Key Companies Profiled

Castle Biosciences, Inc.
Bausch Health Companies, Inc. (DermTech, Inc.)
Canfield Scientific, Inc.
DermaSensor, Inc.
F. Hoffmann-La Roche Ltd.
NeoGenomics, Inc.
Quest Diagnostics Incorporated.
Digital Diagnostics, Inc. (3Derm Systems, Inc.)
FotoFinder Systems GmbH
Veriskin Inc

Global Skin Cancer Diagnostics Market Report Segmentation

By Type

Non-Melanoma
Melanoma

By Test Type

Skin Biopsy
Imaging Tests
Dermatoscopy
Lymph Node Biopsy
Others

By End-use

Hospital & Clinics
Laboratories
Others

By Geography

North America
- US
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 Global Skin Cancer Diagnostics Market, by Type
- 1.4.2 Global Skin Cancer Diagnostics Market, by Test Type
- 1.4.3 Global Skin Cancer Diagnostics Market, by End-use
- 1.4.4 Global Skin Cancer Diagnostics Market, by Geography
1.5 Methodology for the research

Chapter 2. Market at a Glance

2.1 Key Highlights

Chapter 3. Market Overview

3.1 Introduction
- 3.1.1 Overview
  - 3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
- 3.2.3 Market Opportunities
- 3.2.4 Market Challenges
3.3 Porter Five Forces Analysis

Chapter 4. Global Skin Cancer Diagnostics Market by Type

4.1 Global Non-Melanoma Market by Region
4.2 Global Melanoma Market by Region

Chapter 5. Global Skin Cancer Diagnostics Market by Test Type

5.1 Global Skin Biopsy Market by Region
5.2 Global Imaging Tests Market by Region
5.3 Global Dermatoscopy Market by Region
5.4 Global Lymph Node Biopsy Market by Region
5.5 Global Others Market by Region

Chapter 6. Global Skin Cancer Diagnostics Market by End-use

6.1 Global Hospital & Clinics Market by Region
6.2 Global Laboratories Market by Region
6.3 Global Others Market by Region

Chapter 7. Global Skin Cancer Diagnostics Market by Region

7.1 North America Skin Cancer Diagnostics Market
- 7.1.1 North America Skin Cancer Diagnostics Market by Type
  - 7.1.1.1 North America Non-Melanoma Market by Country
  - 7.1.1.2 North America Melanoma Market by Country
- 7.1.2 North America Skin Cancer Diagnostics Market by Test Type
  - 7.1.2.1 North America Skin Biopsy Market by Country
  - 7.1.2.2 North America Imaging Tests Market by Country
  - 7.1.2.3 North America Dermatoscopy Market by Country
  - 7.1.2.4 North America Lymph Node Biopsy Market by Country
  - 7.1.2.5 North America Others Market by Country
- 7.1.3 North America Skin Cancer Diagnostics Market by End-use
  - 7.1.3.1 North America Hospital & Clinics Market by Country
  - 7.1.3.2 North America Laboratories Market by Country
  - 7.1.3.3 North America Others Market by Country
- 7.1.4 North America Skin Cancer Diagnostics Market by Country
  - 7.1.4.1 US Skin Cancer Diagnostics Market
    - 7.1.4.1.1 US Skin Cancer Diagnostics Market by Type
    - 7.1.4.1.2 US Skin Cancer Diagnostics Market by Test Type
    - 7.1.4.1.3 US Skin Cancer Diagnostics Market by End-use
  - 7.1.4.2 Canada Skin Cancer Diagnostics Market
    - 7.1.4.2.1 Canada Skin Cancer Diagnostics Market by Type
    - 7.1.4.2.2 Canada Skin Cancer Diagnostics Market by Test Type
    - 7.1.4.2.3 Canada Skin Cancer Diagnostics Market by End-use
  - 7.1.4.3 Mexico Skin Cancer Diagnostics Market
    - 7.1.4.3.1 Mexico Skin Cancer Diagnostics Market by Type
    - 7.1.4.3.2 Mexico Skin Cancer Diagnostics Market by Test Type
    - 7.1.4.3.3 Mexico Skin Cancer Diagnostics Market by End-use
  - 7.1.4.4 Rest of North America Skin Cancer Diagnostics Market
    - 7.1.4.4.1 Rest of North America Skin Cancer Diagnostics Market by Type
    - 7.1.4.4.2 Rest of North America Skin Cancer Diagnostics Market by Test Type
    - 7.1.4.4.3 Rest of North America Skin Cancer Diagnostics Market by End-use
7.2 Europe Skin Cancer Diagnostics Market
- 7.2.1 Europe Skin Cancer Diagnostics Market by Type
  - 7.2.1.1 Europe Non-Melanoma Market by Country
  - 7.2.1.2 Europe Melanoma Market by Country
- 7.2.2 Europe Skin Cancer Diagnostics Market by Test Type
  - 7.2.2.1 Europe Skin Biopsy Market by Country
  - 7.2.2.2 Europe Imaging Tests Market by Country
  - 7.2.2.3 Europe Dermatoscopy Market by Country
  - 7.2.2.4 Europe Lymph Node Biopsy Market by Country
  - 7.2.2.5 Europe Others Market by Country
- 7.2.3 Europe Skin Cancer Diagnostics Market by End-use
  - 7.2.3.1 Europe Hospital & Clinics Market by Country
  - 7.2.3.2 Europe Laboratories Market by Country
  - 7.2.3.3 Europe Others Market by Country
- 7.2.4 Europe Skin Cancer Diagnostics Market by Country
  - 7.2.4.1 Germany Skin Cancer Diagnostics Market
    - 7.2.4.1.1 Germany Skin Cancer Diagnostics Market by Type
    - 7.2.4.1.2 Germany Skin Cancer Diagnostics Market by Test Type
    - 7.2.4.1.3 Germany Skin Cancer Diagnostics Market by End-use
  - 7.2.4.2 UK Skin Cancer Diagnostics Market
    - 7.2.4.2.1 UK Skin Cancer Diagnostics Market by Type
    - 7.2.4.2.2 UK Skin Cancer Diagnostics Market by Test Type
    - 7.2.4.2.3 UK Skin Cancer Diagnostics Market by End-use
  - 7.2.4.3 France Skin Cancer Diagnostics Market
    - 7.2.4.3.1 France Skin Cancer Diagnostics Market by Type
    - 7.2.4.3.2 France Skin Cancer Diagnostics Market by Test Type
    - 7.2.4.3.3 France Skin Cancer Diagnostics Market by End-use
  - 7.2.4.4 Russia Skin Cancer Diagnostics Market
    - 7.2.4.4.1 Russia Skin Cancer Diagnostics Market by Type
    - 7.2.4.4.2 Russia Skin Cancer Diagnostics Market by Test Type
    - 7.2.4.4.3 Russia Skin Cancer Diagnostics Market by End-use
  - 7.2.4.5 Spain Skin Cancer Diagnostics Market
    - 7.2.4.5.1 Spain Skin Cancer Diagnostics Market by Type
    - 7.2.4.5.2 Spain Skin Cancer Diagnostics Market by Test Type
    - 7.2.4.5.3 Spain Skin Cancer Diagnostics Market by End-use
  - 7.2.4.6 Italy Skin Cancer Diagnostics Market
    - 7.2.4.6.1 Italy Skin Cancer Diagnostics Market by Type
    - 7.2.4.6.2 Italy Skin Cancer Diagnostics Market by Test Type
    - 7.2.4.6.3 Italy Skin Cancer Diagnostics Market by End-use
  - 7.2.4.7 Rest of Europe Skin Cancer Diagnostics Market
    - 7.2.4.7.1 Rest of Europe Skin Cancer Diagnostics Market by Type
    - 7.2.4.7.2 Rest of Europe Skin Cancer Diagnostics Market by Test Type
    - 7.2.4.7.3 Rest of Europe Skin Cancer Diagnostics Market by End-use
7.3 Asia Pacific Skin Cancer Diagnostics Market
- 7.3.1 Asia Pacific Skin Cancer Diagnostics Market by Type
  - 7.3.1.1 Asia Pacific Non-Melanoma Market by Country
  - 7.3.1.2 Asia Pacific Melanoma Market by Country
- 7.3.2 Asia Pacific Skin Cancer Diagnostics Market by Test Type
  - 7.3.2.1 Asia Pacific Skin Biopsy Market by Country
  - 7.3.2.2 Asia Pacific Imaging Tests Market by Country
  - 7.3.2.3 Asia Pacific Dermatoscopy Market by Country
  - 7.3.2.4 Asia Pacific Lymph Node Biopsy Market by Country
  - 7.3.2.5 Asia Pacific Others Market by Country
- 7.3.3 Asia Pacific Skin Cancer Diagnostics Market by End-use
  - 7.3.3.1 Asia Pacific Hospital & Clinics Market by Country
  - 7.3.3.2 Asia Pacific Laboratories Market by Country
  - 7.3.3.3 Asia Pacific Others Market by Country
- 7.3.4 Asia Pacific Skin Cancer Diagnostics Market by Country
  - 7.3.4.1 China Skin Cancer Diagnostics Market
    - 7.3.4.1.1 China Skin Cancer Diagnostics Market by Type
    - 7.3.4.1.2 China Skin Cancer Diagnostics Market by Test Type
    - 7.3.4.1.3 China Skin Cancer Diagnostics Market by End-use
  - 7.3.4.2 Japan Skin Cancer Diagnostics Market
    - 7.3.4.2.1 Japan Skin Cancer Diagnostics Market by Type
    - 7.3.4.2.2 Japan Skin Cancer Diagnostics Market by Test Type
    - 7.3.4.2.3 Japan Skin Cancer Diagnostics Market by End-use
  - 7.3.4.3 India Skin Cancer Diagnostics Market
    - 7.3.4.3.1 India Skin Cancer Diagnostics Market by Type
    - 7.3.4.3.2 India Skin Cancer Diagnostics Market by Test Type
    - 7.3.4.3.3 India Skin Cancer Diagnostics Market by End-use
  - 7.3.4.4 South Korea Skin Cancer Diagnostics Market
    - 7.3.4.4.1 South Korea Skin Cancer Diagnostics Market by Type
    - 7.3.4.4.2 South Korea Skin Cancer Diagnostics Market by Test Type
    - 7.3.4.4.3 South Korea Skin Cancer Diagnostics Market by End-use
  - 7.3.4.5 Singapore Skin Cancer Diagnostics Market
    - 7.3.4.5.1 Singapore Skin Cancer Diagnostics Market by Type
    - 7.3.4.5.2 Singapore Skin Cancer Diagnostics Market by Test Type
    - 7.3.4.5.3 Singapore Skin Cancer Diagnostics Market by End-use
  - 7.3.4.6 Malaysia Skin Cancer Diagnostics Market
    - 7.3.4.6.1 Malaysia Skin Cancer Diagnostics Market by Type
    - 7.3.4.6.2 Malaysia Skin Cancer Diagnostics Market by Test Type
    - 7.3.4.6.3 Malaysia Skin Cancer Diagnostics Market by End-use
  - 7.3.4.7 Rest of Asia Pacific Skin Cancer Diagnostics Market
    - 7.3.4.7.1 Rest of Asia Pacific Skin Cancer Diagnostics Market by Type
    - 7.3.4.7.2 Rest of Asia Pacific Skin Cancer Diagnostics Market by Test Type
    - 7.3.4.7.3 Rest of Asia Pacific Skin Cancer Diagnostics Market by End-use
7.4 LAMEA Skin Cancer Diagnostics Market
- 7.4.1 LAMEA Skin Cancer Diagnostics Market by Type
  - 7.4.1.1 LAMEA Non-Melanoma Market by Country
  - 7.4.1.2 LAMEA Melanoma Market by Country
- 7.4.2 LAMEA Skin Cancer Diagnostics Market by Test Type
  - 7.4.2.1 LAMEA Skin Biopsy Market by Country
  - 7.4.2.2 LAMEA Imaging Tests Market by Country
  - 7.4.2.3 LAMEA Dermatoscopy Market by Country
  - 7.4.2.4 LAMEA Lymph Node Biopsy Market by Country
  - 7.4.2.5 LAMEA Others Market by Country
- 7.4.3 LAMEA Skin Cancer Diagnostics Market by End-use
  - 7.4.3.1 LAMEA Hospital & Clinics Market by Country
  - 7.4.3.2 LAMEA Laboratories Market by Country
  - 7.4.3.3 LAMEA Others Market by Country
- 7.4.4 LAMEA Skin Cancer Diagnostics Market by Country
  - 7.4.4.1 Brazil Skin Cancer Diagnostics Market
    - 7.4.4.1.1 Brazil Skin Cancer Diagnostics Market by Type
    - 7.4.4.1.2 Brazil Skin Cancer Diagnostics Market by Test Type
    - 7.4.4.1.3 Brazil Skin Cancer Diagnostics Market by End-use
  - 7.4.4.2 Argentina Skin Cancer Diagnostics Market
    - 7.4.4.2.1 Argentina Skin Cancer Diagnostics Market by Type
    - 7.4.4.2.2 Argentina Skin Cancer Diagnostics Market by Test Type
    - 7.4.4.2.3 Argentina Skin Cancer Diagnostics Market by End-use
  - 7.4.4.3 UAE Skin Cancer Diagnostics Market
    - 7.4.4.3.1 UAE Skin Cancer Diagnostics Market by Type
    - 7.4.4.3.2 UAE Skin Cancer Diagnostics Market by Test Type
    - 7.4.4.3.3 UAE Skin Cancer Diagnostics Market by End-use
  - 7.4.4.4 Saudi Arabia Skin Cancer Diagnostics Market
    - 7.4.4.4.1 Saudi Arabia Skin Cancer Diagnostics Market by Type
    - 7.4.4.4.2 Saudi Arabia Skin Cancer Diagnostics Market by Test Type
    - 7.4.4.4.3 Saudi Arabia Skin Cancer Diagnostics Market by End-use
  - 7.4.4.5 South Africa Skin Cancer Diagnostics Market
    - 7.4.4.5.1 South Africa Skin Cancer Diagnostics Market by Type
    - 7.4.4.5.2 South Africa Skin Cancer Diagnostics Market by Test Type
    - 7.4.4.5.3 South Africa Skin Cancer Diagnostics Market by End-use
  - 7.4.4.6 Nigeria Skin Cancer Diagnostics Market
    - 7.4.4.6.1 Nigeria Skin Cancer Diagnostics Market by Type
    - 7.4.4.6.2 Nigeria Skin Cancer Diagnostics Market by Test Type
    - 7.4.4.6.3 Nigeria Skin Cancer Diagnostics Market by End-use
  - 7.4.4.7 Rest of LAMEA Skin Cancer Diagnostics Market
    - 7.4.4.7.1 Rest of LAMEA Skin Cancer Diagnostics Market by Type
    - 7.4.4.7.2 Rest of LAMEA Skin Cancer Diagnostics Market by Test Type
    - 7.4.4.7.3 Rest of LAMEA Skin Cancer Diagnostics Market by End-use

Chapter 8. Company Profiles

8.1 Castle Biosciences, Inc.
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Research & Development Expenses
- 8.1.4 Recent strategies and developments:
  - 8.1.4.1 Product Launches and Product Expansions:
  - 8.1.4.2 Acquisition and Mergers:
- 8.1.5 SWOT Analysis
8.2 Bausch Health Companies, Inc.(DermTech, Inc.)
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Segmental and Regional Analysis
- 8.2.4 Research & Development Expense
- 8.2.5 SWOT Analysis
8.3 Canfield Scientific, Inc.
- 8.3.1 Company Overview
- 8.3.2 SWOT Analysis
8.4 DermaSensor, Inc.
- 8.4.1 Company Overview
- 8.4.2 SWOT Analysis
8.5 F. Hoffmann-La Roche Ltd.
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Segmental and Regional Analysis
- 8.5.4 Research & Development Expense
- 8.5.5 Recent strategies and developments:
  - 8.5.5.1 Partnerships, Collaborations, and Agreements:
- 8.5.6 SWOT Analysis
8.6 Neogenomics, Inc.
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Segmental Analysis
- 8.6.4 Research & Development Expenses
- 8.6.5 SWOT Analysis
8.7 Quest Diagnostics Incorporated
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Segmental Analysis
- 8.7.4 Recent strategies and developments:
  - 8.7.4.1 Partnerships, Collaborations, and Agreements:
  - 8.7.4.2 Acquisition and Mergers:
- 8.7.5 SWOT Analysis
8.8 Digital Diagnostics, Inc.(3Derm Systems, Inc.)
- 8.8.1 Company Overview
8.9 FotoFinder Systems GmbH
- 8.9.1 Company Overview
- 8.9.2 SWOT Analysis
8.10. VERISKIN INC.
- 8.10.1 Company Overview
- 8.10.2 SWOT Analysis

Chapter 9. Winning Imperatives for Skin Cancer Diagnostics Market

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 3,600

￦ 5,208,000

PDF (Multi User License)

PDF 보고서를 동일 기업의 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,320

￦ 6,250,000

PDF (Corporate User License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,048

￦ 8,750,000

※ 부가세 별도

세계의 피부암 진단 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 검사 유형별, 최종 용도별, 지역별, 전망과 예측(2024-2031년)

Global Skin Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type, By Test Type, By End-use, By Regional Outlook and Forecast, 2024 - 2031

목차

제1장 시장 범위와 조사 방법

제2장 시장 개관

제3장 시장 개요

제4장 세계 시장 : 유형별

제5장 세계 시장 : 검사 유형별

제6장 세계 시장 : 최종 용도별

제7장 세계 시장 : 지역별